14-06-2022 | EULAR 2022 | Conference coverage | Video
The BE MOBILE 1 and 2 trials of bimekizumab in axSpA
Désirée van der Heijde outlines the findings of two phase 3 trials demonstrating that bimekizumab may be beneficial for patients with nonradiographic axial spondyloarthritis or ankylosing spondylitis (2:54).